Effect of Paroxetine on Smokers' Cardiovascular Response to Stress - 1
Tobacco Use Disorder
About this trial
This is an interventional treatment trial for Tobacco Use Disorder focused on measuring Smoking
Eligibility Criteria
Inclusion Criteria: Smokes an average of at least 10 cigarettes per day during the year prior to enrollment Exclusion Criteria: Interested in quitting smoking within the 3 months following enrollment Current unstable medical condition Substance abuse within the year prior to enrollment Current use of any medications (e.g., psychoactive medications, antihypertensives) that, in the opinion of the investigators, might interfere with study measures or that would be expected to interact with paroxetine (e.g., CYP2D6 substrates) Smoking cessation therapy within the 3 months prior to enrollment Regular use of any form of tobacco other than cigarettes Significant psychiatric disorders as assessed by the PRIME-MD and verified by a clinician History of hypersensitivity to any selective serotonin reuptake inhibitor Pregnancy or breastfeeding
Sites / Locations
- College of Pharmacy
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
1
2
Active medication for 4 weeks followed by placebo for 4 weeks
Placebo for 4 weeks followed by active for 4 weeks